Investigational drug · Phase 3
ESG401
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC), Neoplasms, Breast.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
4
Any phase or sponsor naming "ESG401"
First trial start
2021
Sep 14, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ESG401", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Breast Cancer
- Triple-Negative Breast Cancer (TNBC)
- Neoplasms, Breast
- Neoplasms, Lung
- Neoplasms,Colorectal
- Neoplasms, Bladder
- Neoplasm of Stomach
- Neoplasms,Ovarian
Approved drugs for the same conditions: Breast cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ESG401" as an intervention, largest first.
- A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast CancerPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06732323 · 504 participants (planned) · Start Sep 4, 2025 · Primary completion Jun 2027
Drug: ESG401; Investigator's Choice Chemotherapy · For: Triple-Negative Breast Cancer (TNBC)
Sites: Beijing, China
- A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast CancerPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06383767 · 378 participants (planned) · Start Jul 11, 2024 · Primary completion Jun 30, 2027
Drug: ESG401; Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice) · For: Metastatic Breast Cancer
Sites: Beijing, China
Shanghai Escugen Biotechnology Co., LtdIndustry
NCT04892342 · 156 participants · Start Sep 14, 2021 · Primary completion Jun 30, 2025
Drug: ESG401 · For: Neoplasms, Breast; Neoplasms, Lung; Neoplasms,Colorectal and 3 more
Sites: Beijing, China; Tianjin, China; Hangzhou, China
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruiting
Peking Union Medical CollegeAcademic, hospital or other
NCT06145308 · 39 participants (planned) · Start Aug 15, 2023 · Primary completion Jul 10, 2028
Drug: Cohort 1 (HER2-positive, RC48-ADC); Cohort 2 (NTRK-fusion or NTRK-mutant) and 18 more · For: Salivary Gland Carcinoma; Precision Therapy
Sites: Beijing, China · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Novel TROP2 antibody-drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising optionਮ.
Wang J, Zhang Y, Bai R, et al. · ESMO Open 2025
- Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer.
Zhao J, Huang F, Xu X, et al. · Front Oncol 2024
- Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors.
Wang J, Tong Z, Tan Y, et al. · Cell Rep Med 2024
Also in development for Metastatic Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- LasofoxifeneAZU-101Phase 34 trials
Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.